Your browser doesn't support javascript.
loading
Further Evidence for RFWD3 Gene Causing Fanconi Anemia Complementation Group W: Detailed Clinical Report of the Second Case in the Literature.
Kocagil, Sinem; Safak, Ikbal Nur; Saraç, Elif; Aydin, Can; Artan, Sevilhan; Kirel, Birgül.
Afiliación
  • Kocagil S; Department of Medical Genetics, Faculty of Medicine, Eskisehir Osmangazi University, Eskisehir, Turkey.
  • Safak IN; Department of Pediatrics, Faculty of Medicine, Eskisehir Osmangazi University, Eskisehir, Turkey.
  • Saraç E; Department of Medical Genetics, Faculty of Medicine, Eskisehir Osmangazi University, Eskisehir, Turkey.
  • Aydin C; Department of Pediatrics, Faculty of Medicine, Eskisehir Osmangazi University, Eskisehir, Turkey.
  • Artan S; Department of Medical Genetics, Faculty of Medicine, Eskisehir Osmangazi University, Eskisehir, Turkey.
  • Kirel B; Department of Pediatrics, Faculty of Medicine, Eskisehir Osmangazi University, Eskisehir, Turkey.
Mol Syndromol ; 14(6): 509-515, 2023 Dec.
Article en En | MEDLINE | ID: mdl-38058754
ABSTRACT

Introduction:

Fanconi anemia (FA) is a heterogeneous genetic disorder that is characterized by progressive bone marrow failure, congenital malformations, predisposition to malignancy, and short stature. The RFWD3 gene was recently associated with FA complementation group W, and only 1 patient is reported in the literature so far. Case Presentation Here, we report the second patient, a 10-year-old male, who has failure to thrive, central nervous system abnormalities, bilateral radial ray defects, urogenital anomalies, facial dysmorphism, and thrombocytopenia. The patient was suspected to have FA according to the aforementioned findings, and the homozygous c.1501C>T variant in the RFWD3 gene was detected by whole-exome sequencing. The diepoxybutane test and mitomycin C-induced peripheral blood cultures revealed 0.46 and 0.90 chromosomal breaks, respectively.

Conclusion:

In this article, clinical findings of the second patient with FA complementation group W are discussed in detail, aiming to expand the clinical and molecular spectrums of the disease.
Palabras clave

Texto completo: 1 Colección: 01-internacional Idioma: En Revista: Mol Syndromol Año: 2023 Tipo del documento: Article País de afiliación: Turquía

Texto completo: 1 Colección: 01-internacional Idioma: En Revista: Mol Syndromol Año: 2023 Tipo del documento: Article País de afiliación: Turquía